Thomas Matthew Habermann

Thomas Matthew Habermann's AcademicInfluence.com Rankings

Philosophy

#6054

World Rank

#9020

Historical Rank

Logic

#3248

World Rank

#4375

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Thomas Matthew Habermann's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Thomas Matthew Habermann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas Matthew Habermann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. (2006) (1298)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. (2006) (1256)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (974)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (2012) (932)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma (2015) (879)
Association of resident fatigue and distress with perceived medical errors. (2009) (844)
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. (2003) (838)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. (2009) (830)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. (2004) (822)
The well-being of physicians. (2003) (715)
Epstein-barr virus-induced posttransplant lymphoproliferative disorders (1999) (475)
Relationship between increased personal well-being and enhanced empathy among internal medicine residents (2005) (389)
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. (2008) (380)
Pretransplantation assessment of the risk of lymphoproliferative disorder. (1995) (377)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. (2014) (363)
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. (2004) (325)
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. (2015) (323)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. (2008) (317)
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (2010) (307)
Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma (2009) (292)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. (2017) (289)
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (280)
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. (2009) (277)
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. (2005) (270)
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. (2014) (269)
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. (2006) (266)
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. (2005) (261)
Relationship between increased personal well-being and enhanced empathy among (2005) (257)
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. (2013) (250)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma (2009) (249)
Post‐Transplantation Lymphoproliferative Disorders in Adults (2018) (248)
Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. (1995) (246)
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. (1995) (243)
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. (2004) (230)
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. (1999) (222)
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma (2010) (218)
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. (2010) (212)
Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 (2015) (206)
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. (2010) (199)
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. (1997) (195)
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. (2005) (191)
Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients (2013) (191)
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. (2012) (190)
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma (2012) (189)
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. (2003) (187)
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma (2016) (180)
The clinical spectrum of Castleman's disease (2012) (180)
Testicular lymphoma is associated with a high incidence of extranodal recurrence (2000) (179)
Orbital lymphoma: radiotherapy outcome and complications. (2001) (178)
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. (2001) (177)
Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. (2005) (175)
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma (2011) (175)
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. (2000) (164)
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. (2013) (163)
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. (2007) (158)
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. (2014) (154)
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. (2002) (148)
Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases? (2005) (148)
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. (2014) (143)
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. (1997) (143)
Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival (2006) (141)
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era (2013) (140)
Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma (2014) (140)
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. (2011) (133)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. (2015) (133)
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. (2014) (132)
Risk of lymphoma in inflammatory bowel disease. (2000) (129)
Adult B-Cell Lymphomas With Burkitt-Like Morphology Are Phenotypically and Genotypically Heterogeneous With Aggressive Clinical Behavior (2005) (128)
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. (2016) (127)
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. (2018) (124)
Primary thyroid lymphoma. (1999) (120)
Absolute lymphocyte count predicts overall survival in follicular lymphomas (2006) (119)
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. (2019) (118)
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. (2007) (116)
GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma (2011) (114)
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation (2010) (114)
Bowel perforation in intestinal lymphoma: incidence and clinical features. (2013) (114)
Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratio (2010) (114)
Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. (2005) (109)
Localization of eosinophil granule major basic protein in human basophils (1983) (108)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. (2019) (108)
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. (2002) (107)
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. (2002) (105)
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. (1987) (101)
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 (2017) (101)
Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. (2014) (101)
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. (2015) (100)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. (2016) (96)
Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. (1996) (93)
Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. (1994) (92)
Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era (2005) (91)
Occult systemic Non-Hodgkin's Lymphoma (NHL) in patients initially diagnosed as Primary Central Nervous System Lymphoma (PCNSL): How much staging is enough? (2005) (89)
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) (2010) (89)
Risk of lymphoma in inflammatory bowel disease (2000) (86)
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. (2015) (85)
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma (2012) (85)
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. (2015) (81)
A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era (2014) (81)
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). (2004) (81)
Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. (1999) (80)
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. (2013) (79)
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. (2018) (78)
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia (2007) (78)
Non-Hodgkin's lymphoma of the thyroid: Is more than biopsy necessary? (1992) (78)
Diffuse Large B-Cell Lymphoma Version 1.2016. (2016) (76)
Antioxidant intake from fruits, vegetables and other sources and risk of non‐Hodgkin's lymphoma: the Iowa Women's Health Study (2009) (75)
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. (2011) (75)
Pulmonary complications of leukemia. (1990) (74)
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. (2018) (74)
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. (1999) (73)
Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor-κB Canonical Pathway and Risk of Non-Hodgkin's Lymphoma (2008) (73)
Natural killer/T-cell lymphoma with ocular and adnexal involvement. (2006) (73)
Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil (2005) (72)
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. (2008) (71)
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. (2012) (70)
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. (2012) (70)
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma (2015) (69)
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease (2019) (68)
Treatment of stage IE primary lymphoma of bone. (1994) (67)
Evaluation of the Coulter Counter model S-Plus IV. (1985) (67)
Smoking, alcohol use, obesity, and overall survival from non‐Hodgkin lymphoma (2010) (66)
Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. (1996) (66)
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte‐predominant Hodgkin lymphoma (2012) (65)
Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma (2013) (64)
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. (2010) (63)
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia (2018) (63)
Association of aspirin and other non‐steroidal anti‐inflammatory drug use with incidence of non‐hodgkin lymphoma (2003) (61)
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas (2007) (61)
The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas (2014) (59)
Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. (2004) (57)
A Prospective Study of the Relationship between Medical Knowledge and Professionalism among Internal Medicine Residents (2007) (56)
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. (2012) (56)
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B‐cell lymphoma (2009) (56)
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma (2010) (55)
Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women (2000) (55)
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma (2015) (55)
A genome-wide association study of marginal zone lymphoma shows association to the HLA region (2015) (55)
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). (2018) (54)
Complementary and alternative medicine use among long‐term lymphoma survivors: A pilot study (2009) (54)
Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. (2016) (53)
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres (2014) (52)
Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis (2001) (52)
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia (2018) (52)
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma (2013) (51)
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma (2012) (50)
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. (2016) (50)
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. (2017) (50)
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement (2020) (50)
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B‐cell lymphoma (2006) (50)
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma (2010) (49)
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma (2014) (49)
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. (2016) (48)
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines (2017) (47)
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. (2011) (46)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials (2018) (46)
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. (2002) (46)
Endobronchial ultrasound and lymphoproliferative disorders: a retrospective study. (2012) (46)
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. (2015) (46)
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. (2021) (45)
Primary Cutaneous Large Cell Lymphomas Morphologic, Immunophenotypic, and Clinical Features of 20 Cases (1994) (45)
Primary central nervous system lymphoma as a variant of Richter's syndrome in two patients with chronic lymphocytic leukemia (1989) (45)
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy (2017) (45)
Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) (2015) (45)
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. (2017) (44)
Neurological complications of peripheral and cutaneous T‐cell lymphomas (1994) (44)
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements (2018) (44)
Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. (2000) (44)
Granulomatous angiitis of the spinal cord associated with Hodgkin's disease (1991) (43)
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. (2015) (42)
A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL). (2007) (42)
Polymorphic reticulosis: a reappraisal. (1994) (42)
Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. (2016) (42)
Primary pulmonary lymphoma. (1999) (42)
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. (2007) (42)
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG) (2016) (42)
Involvement of the Lacrimal Drainage System by Leukemia or Lymphoma (2002) (41)
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. (2011) (41)
Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis. (2006) (41)
Lymphoma in soft tissue: a clinicopathologic study of 19 cases. (1996) (41)
Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia (1992) (40)
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404) (2014) (40)
Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma (2016) (39)
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort (2014) (39)
New developments in the management of diffuse large B-cell lymphoma (2012) (39)
Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method. (1990) (39)
If you feed them, they will come: A prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center (2007) (38)
Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation (2013) (38)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). (2015) (37)
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 (2021) (37)
Strategies for improving attendance at medical grand rounds at an academic medical center. (2003) (37)
Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma (2012) (36)
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2013) (36)
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma (2012) (36)
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients (2017) (36)
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis (2013) (36)
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP (2019) (36)
Food‐frequency questionnaire‐based estimates of total antioxidant capacity and risk of non‐Hodgkin lymphoma (2012) (36)
Nasal and Nasopharyngeal Angiocentric T‐Cell Lymphomas (1996) (35)
Primary Laryngeal Lymphoma (1997) (35)
Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma. (2013) (35)
Elevated pretreatment serum levels of interferon‐inducible protein‐10 (CXCL10) predict disease relapse and prognosis in diffuse large B‐cell lymphoma patients (2012) (35)
Epidemiology of Marginal Zone Lymphoma. (2021) (34)
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement (2020) (34)
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. (1999) (34)
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers (2018) (34)
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes (2020) (34)
Lymphoma Involving the Esophagus (1994) (33)
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. (2019) (32)
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). (2015) (32)
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma (2013) (32)
mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001). (2007) (32)
Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 (2016) (32)
A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma. (2000) (31)
Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma. (2006) (31)
Lymphoma‐associated skin cancer: incidence, natural history, and clinical management (2014) (31)
Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (31)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (2008) (30)
Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa Women's Health Study (United States) (2002) (30)
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma (2011) (30)
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials (2018) (30)
Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494 (2010) (30)
Current status of medical grand rounds in departments of medicine at US medical schools. (2006) (29)
Severe neuropathy associated with low-dose recombinant interferon-alpha. (1989) (29)
Phase I Study of Interleukin-12 in combination with Rituximab in patients with B-cell non-Hodgkin lymphoma (2001) (29)
Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018 (2018) (29)
Posttransplant Lymphoproliferative Disorder Following Pancreas Transplantation (2009) (29)
Blood transfusion and risk of non-Hodgkin's lymphoma. (1999) (28)
PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485) (2015) (28)
Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496) (2016) (28)
Therapeutic options in patients with lymphoma and severe liver dysfunction. (2004) (28)
Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation (2012) (28)
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas (2007) (27)
Adrenal insufficiency as a manifestation of disseminated non-Hodgkin's lymphoma. (1997) (27)
Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. (2019) (27)
Medical residents' emotional well-being. (2002) (27)
Primary systemic amyloidosis in patients with Waldenström macroglobulinemia (2018) (27)
Long-Term Foliow-Up of a CHOP-Based Regimen with Maintenance Therapy and Central Nervous System Prophylaxis in Lymphoblastic Non-Hodgkin's Lymphoma (1994) (27)
Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (26)
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma (2019) (25)
Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses (2011) (25)
A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region (2012) (25)
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. (2017) (25)
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. (2015) (25)
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. (1996) (24)
Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma (2012) (24)
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma. (2016) (24)
Peripheral T‐cell lymphoma involving the placenta (1992) (24)
Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial (2012) (24)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types (2015) (24)
Mayo Clinic Internal Medicine Concise Textbook (2007) (23)
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma (2019) (23)
Splenectomy for Massive Splenomegaly: Long-Term Results and Risks for Mortality (2013) (23)
Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. (2019) (23)
History of autoimmune conditions and lymphoma prognosis (2018) (22)
Secondary intramedullary spinal cord non-Hodgkin’s lymphoma (2012) (22)
Human Pegivirus infection and lymphoma risk and prognosis: a North American study (2018) (22)
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma (2017) (22)
Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma (2007) (21)
Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma (2014) (21)
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia (2017) (21)
Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial (2007) (20)
Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. (2010) (20)
Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study (2017) (20)
Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update (2007) (20)
Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma. (2019) (20)
Treatment of late‐stage Sézary syndrome with 2‐Chlorodeoxyadenosine (2002) (20)
Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma (2017) (19)
Survival in patients with limited-stage peripheral T-cell lymphomas (2015) (19)
Management of stage IE primary gastric lymphoma. (1995) (19)
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia (2018) (19)
A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial (2013) (19)
The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. (2012) (18)
Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström’s macroglobulinemia (2008) (18)
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. (2019) (18)
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. (2013) (18)
Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma (2001) (18)
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia (2019) (18)
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ‘indeterminate’ reports (2010) (18)
Risk of non‐Hodgkin lymphoma in association with germline variation in complement genes (2009) (18)
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas (2019) (17)
Cytogenetic findings in 21 cases of peripheral T‐Cell lymphoma (1990) (17)
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). (2002) (17)
PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma (2017) (17)
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B‐ and T‐cell non‐Hodgkin lymphoma (2014) (17)
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. (1994) (17)
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression (2017) (17)
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? (2020) (16)
Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL (2020) (16)
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma (2021) (16)
Prevalence, clinical characteristics and prognosis of EBV‐positive follicular lymphoma (2018) (16)
Acute Granulomatous Interstitial Nephritis Secondary to Bisphosphonate Alendronate Sodium (2005) (16)
Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma (2017) (16)
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma (2007) (16)
Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study (2012) (15)
The mTORC 1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma (2015) (15)
Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors (2015) (15)
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494) (2017) (15)
Lenalidomide-associated hypothyroidism (2007) (15)
Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. (1994) (15)
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (15)
Risk of histological transformation and therapy‐related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma (2017) (15)
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone (2007) (14)
Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
Chapter 111 – Peripheral Neuropathy Associated with Lymphoma, Leukemia, and Myeloproliferative Disorders (2005) (14)
R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793 (2010) (14)
Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. (2009) (14)
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) (2017) (14)
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2014) (13)
Inherited genetic variation and overall survival following follicular lymphoma (2012) (13)
Laparoscopic biopsy for suspected abdominal lymphoma. (1998) (13)
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts (2018) (13)
Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia (2018) (13)
PARANEOPLASTIC SARCOID-LIKE REACTIONS AND THE EYE (2015) (13)
Utility of post-therapy surveillance scans in DLBCL. (2013) (13)
PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485) (2016) (13)
Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma (2019) (13)
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. (2011) (13)
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? (2021) (12)
Cryptococcus neoformans infections in patients with lymphoproliferative neoplasms (2018) (12)
Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era (2014) (12)
Faculty Opinions recommendation of Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. (2010) (12)
Epstein-Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report. (2007) (12)
Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure. (1989) (12)
Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma (2019) (12)
The association of physical activity before and after lymphoma diagnosis with survival outcomes (2018) (12)
FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts (2017) (12)
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 (2020) (11)
Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study. (2019) (11)
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index. (1991) (11)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients (2020) (11)
A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma. (2009) (11)
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy (2017) (11)
The utility of restaging bone marrow biopsy in PET‐negative patients with diffuse large B‐cell lymphoma and baseline bone marrow involvement (2014) (11)
Risk of cutaneous T‐cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non‐Hodgkin lymphoma (2017) (11)
Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma (2008) (10)
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. (2020) (10)
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients (2020) (10)
Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. (2021) (10)
Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. (2006) (10)
Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma (2019) (10)
Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era (2019) (10)
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era: Primary CNS PTLD (2013) (10)
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma (2018) (10)
Marginal zone lymphoma: present status and future perspectives. (2022) (9)
Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274). (2006) (9)
Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease (2015) (9)
Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494). (2004) (9)
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. (2022) (9)
Peripheral T‐cell lymphoma involving the placenta (1993) (9)
Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival (2018) (9)
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia (2021) (9)
Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). (2004) (9)
Secondary Epstein‐Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat (2012) (9)
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? (2020) (8)
mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein‐Barr virus‐driven lymphoproliferative disorders (EBV‐LPD) (2008) (8)
Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity (2012) (8)
Pulmonary lymphoma: Primary and systemic disease (1997) (8)
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma (2006) (8)
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–Barr virus status (2013) (8)
Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma. (2005) (8)
Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study. (2014) (8)
Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome (2013) (8)
Posttransplant lymphoproliferative disorders. (2008) (7)
Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. (1988) (7)
Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia (2021) (7)
G-CSF Administration Increases Pulmonary Toxicity for Hodgkin’s Disease Patients Treated with Bleomycin-Containing Chemotherapy. (2004) (7)
Antibody therapy in aggressive lymphomas. (2007) (7)
Is rituximab one for all ages and each sex? (2014) (7)
Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). (2016) (7)
S‐phase fraction by the labeling index as a predictive factor for progression and survival in low grade non‐Hodgkin's lymphoma (1995) (7)
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study. (2011) (7)
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. (2020) (7)
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis (2011) (7)
Fulminant Hepatic Failure Secondary to Adenovirus Following Fludarabine-Based Chemotherapy for Non-Hodgkin's Lymphoma (2001) (7)
Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials (2016) (6)
Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers (2017) (6)
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type (2021) (6)
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era (2012) (6)
Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma (2016) (6)
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue (2017) (6)
A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group (2017) (6)
Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. (2016) (6)
Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma. (2006) (6)
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma (2021) (6)
Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma. (2009) (6)
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL) (2019) (6)
The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project (2017) (6)
Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection (2021) (6)
Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment. (2007) (5)
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States (2018) (5)
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? (2022) (5)
Analysis and impact of a multidisciplinary lymphoma virtual tumor board (2020) (5)
In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy (2013) (5)
Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era (2011) (5)
Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria (2021) (5)
Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). (2019) (5)
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma (2018) (5)
Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index. (1999) (5)
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes (2021) (5)
Impact of lymphoma survivorship clinic visit on patient-centered outcomes (2019) (5)
Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma. (2009) (5)
Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma. (2007) (5)
A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results (2013) (5)
Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404) (2012) (4)
IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era (2013) (4)
Clinical Features and Treatment Approaches in Patients with Rosai-Dorfman Disease: The Mayo Clinic Experience (2017) (4)
Diffuse large B-cell lymphoma. (2005) (4)
Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance) (2015) (4)
Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women (2015) (4)
A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas (2010) (4)
Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL) (2008) (4)
Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas) (2016) (4)
A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL). (2007) (4)
Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma (2021) (4)
The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma (2011) (4)
Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy (2015) (4)
Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493) (2012) (4)
Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC) (2019) (4)
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma (2019) (4)
Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma. (2004) (4)
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era (2018) (4)
Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma (2010) (4)
Non-Hodgkin's lymphoma: present status and future prospects. (1999) (4)
Impact of lymphoma survivorship clinic visit on patient-centered outcomes. (2016) (4)
Genetically Determined Height and Risk of Non-hodgkin Lymphoma (2020) (4)
Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (2014) (4)
Education scholarship. (2006) (4)
Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma (2010) (4)
A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome (2022) (3)
Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant. (2009) (3)
Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy (2011) (3)
Prognostic Indices in Older DLBCL Patients Receiving R-CHOP: An Analysis of the U.S. Intergroup Study (E4494, CALGB 9793). (2006) (3)
Authors’ response (2006) (3)
Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. (2021) (3)
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. (2022) (3)
Images and reflections from Mayo Clinic heritage. (2001) (3)
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? (2018) (3)
EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE (2012) (3)
Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD) (2018) (3)
Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center (2021) (3)
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era (2021) (3)
FDG-PET as predictor of outcome in diffuse large B-cell lymphoma (DLBCL): First analysis of “indeterminate” reports (2008) (3)
Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis (2017) (3)
Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma (2014) (3)
Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients (2011) (3)
Participation in clinical trials to improve outcomes of patients with relapsed lymphoma. (2016) (3)
Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma (2021) (3)
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting (2018) (3)
Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource (2015) (3)
Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM) (2016) (3)
Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma. (2007) (3)
A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma. (1998) (3)
Improving Attendance at Medical Grand Rounds: In Response (2003) (3)
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database (2019) (3)
Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients (2010) (3)
Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy. (2005) (3)
Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG (2011) (3)
Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population (2012) (3)
CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE (2019) (3)
The Management of Gastric Lymphoma (1993) (3)
Body mass index and survival of patients with lymphoma (2020) (3)
Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab (2012) (3)
Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy. (2012) (3)
The Mutational Landscape of Diffuse Large B Cell Lymphoma (2011) (3)
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma (2018) (3)
Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials (2017) (3)
Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL) (2020) (3)
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary CNS Lymphoma: A Mayo Clinic Experience. (2020) (3)
Widespread use of complementary and alternative medicine (CAM) among non-Hodgkin lymphoma (NHL) survivors. (2012) (3)
CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS (2017) (3)
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma (2021) (3)
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia (2020) (3)
The association of health behaviors with quality of life in lymphoma survivors (2020) (3)
PERIPHERAL T-CELL LYMPHOMA INVOLVING THE PLACENTA. AUTHORS'S REPLY (1993) (3)
Predictors of short-term survival in Waldenström Macroglobulinemia (2020) (3)
Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma (2019) (2)
Molecular proﬁling of diffuse large B-cell lymphoma identiﬁes robust subtypes including one characterized by host inﬂammatory response (2005) (2)
Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). (2007) (2)
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome (2021) (2)
High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant. (2007) (2)
Images and reflections from Mayo Clinic heritage. (2002) (2)
Complementary and Alternative Medicine Use among Long-Term Survivors: A Pilot Study (2011) (2)
Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. (2016) (2)
Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494 (2007) (2)
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) (2013) (2)
Bone involvement on PET/CT predicts event‐free survival in follicular lymphoma Grade 3B (2020) (2)
Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy (2017) (2)
A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma (2014) (2)
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. (2022) (2)
Older patients and risk of developing and dying from bleomycin-induced lung toxicity. (2014) (2)
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY (2019) (2)
High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease? (2018) (2)
Outcomes in mantle cell lymphoma with central nervous system involvement. (2021) (2)
Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients (2016) (2)
Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era (2015) (2)
Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma (2013) (2)
A Pilot Study of Physical Activity Level and Mood among Long-Term Lymphoma Survivors. (2005) (2)
QOL at 3 years after diagnosis in aggressive lymphoma survivors. (2015) (2)
Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia (2016) (2)
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (2022) (2)
Central nervous system involvement by mantle cell lymphoma (2021) (2)
A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results (2013) (2)
Treatment of idiopathic urticaria, angioedema and anaphylaxis with cladribine (2002) (2)
Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma (2019) (2)
Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. (1992) (2)
Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution (2012) (2)
Host Genetic Variation in the Cell Cycle and NF-κB Pathways and Overall Survival in Mantle Cell Lymphoma. (2007) (2)
Rational Therapeutic Targets in Large B-Cell and Mantle Cell Lymphomas (2007) (2)
Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation (2022) (2)
Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (2012) (2)
Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). (2011) (2)
Preliminary results from two phase II studies of lenalidomide monotherapy in relapsed/refractory non-Hodgkin's Lymphoma. (2006) (2)
Clinical Characteristics of Familial vs. Sporadic non-Hodgkin lymphoma in Patients Diagnosed at The Mayo Clinic (1986 – 2000) (2004) (2)
How I treat cardiovascular complications in patients with lymphoid malignancies. (2021) (2)
Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis (2020) (2)
CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma (2013) (2)
An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation (2018) (2)
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type (2021) (2)
A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study (2013) (2)
Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (2016) (2)
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy (2015) (2)
Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. (2013) (2)
lymphoma: an Eastern Cooperative Oncology Group trial (E3493) in patients with poor-prognosis, intermediate-grade non-Hodgkin Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide (2013) (2)
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era (2021) (2)
Human Pegivirus (HPgV) Infection and Lymphoma Risk and Prognosis: A Study from North America (2017) (1)
Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience (2019) (1)
Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients (2011) (1)
The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival (2017) (1)
Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas (2018) (1)
Report from the Lymphoma Research Foundation Adolescent and Young Adult (AYA) Lymphoma Scientific Workshop, May 2019 (2020) (1)
Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM). (2016) (1)
SOMATIC ALTERATIONS IN FOLLICULAR LYMPHOMA ASSOCIATE WITH UNIQUE TUMOR‐CELL TRANCRIPTIONAL STATES AND TUMOR‐IMMUNE MICROENVIRONMENTS (2021) (1)
Primary Cutaneous Lymphoma (2014) (1)
Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors (2011) (1)
Impact of international collaboration utilizing E-consult and E-tumor board in the multidisciplinary management of cancer patients: A study from Mayo Clinic Care Network (MCCN) members. (2019) (1)
Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era (2018) (1)
Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Composite Histology Have Improved Early Outcome Compared to De Novo DLBCL When Treated with R-CHOP (2008) (1)
Abstract 2536: Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study (IWHS) cohort. (2013) (1)
Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era (2021) (1)
Quality of Life Concerns of Long-Term Lymphoma Survivors: Results of a Pilot Study. (2005) (1)
Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model (2018) (1)
Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience (2010) (1)
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study (2022) (1)
Images and reflections from Mayo Clinic Heritage. Henry S. Plummer. (2002) (1)
Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma (2020) (1)
Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study (2021) (1)
Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile. (2020) (1)
Impact of Early Rasburicase on Incidence and Outcomes of Clinical Tumor Lysis Syndrome in Lymphoma (2018) (1)
Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma (2017) (1)
Predictors of Hyperviscosity Syndrome (HVS) in Waldenström Macroglobulinemia (WM) (2017) (1)
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018) (2022) (1)
Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL (2018) (1)
target in diffuse large B-cell lymphoma SYK-dependent tonic B-cell receptor signaling is a rational treatment (2013) (1)
Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma (2008) (1)
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study (2019) (1)
Post-Transplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract: 1186 (2017) (1)
A roadmap for clinical trial design in marginal zone lymphoma (2022) (1)
Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL (2016) (1)
Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas (2020) (1)
Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience (2011) (1)
Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs). (2020) (1)
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation (2022) (1)
Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study (2011) (1)
Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis (2016) (1)
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care (2022) (1)
GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS (2013) (1)
MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras. (2009) (1)
ACUTE CORONARY SYNDROME IN ACTIVE HEMATOLOGICAL MALIGNANCIES: A COHORT STUDY OF 5,300 PATIENTS (2016) (1)
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study (2018) (1)
Depth of Response in Waldenstrom Macroglobulinemia (2018) (1)
DO CELL‐OF‐ORIGIN, DOUBLE EXPRESSER, AND DOUBLE HIT STATUS AFFECT OUTCOMES IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL)? A PROSPECTIVE OBSERVATIONAL STUDY (2021) (1)
Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study (2015) (1)
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance) (2020) (1)
Cancer Therapy : Clinical Phase I Study of Ipilimumab , an Anti – CTLA-4 Monoclonal Antibody , in Patients with Relapsed and Refractory B-Cell Non – Hodgkin Lymphoma (2009) (1)
High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials (2018) (1)
Faculty Opinions recommendation of Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. (2007) (1)
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts (2021) (1)
Images and reflections from Mayo Clinic heritage. (2003) (1)
Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma. (2009) (1)
Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma, (2011) (1)
Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab (2021) (1)
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (1)
Primary Diffuse Large B-Cell Lymphoma of the Colon: Surgery for Local Disease Control Does Not Improve Outcome. (2007) (1)
Vaccination History and Risk of Lymphoma and Its Major Subtypes (2021) (1)
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study (2021) (1)
Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience (2011) (1)
Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values (2019) (1)
Abstract 2811: Vitamin K intake and risk of non-Hodgkin lymphoma (NHL) (2010) (1)
Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome (2017) (1)
Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis. (2018) (1)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy (2014) (1)
Expression of p 21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP : A Prospective ECOG and Southwest Oncology Group Correlative Study on E 4494 (2010) (1)
State-of-the-art treatments in non-Hodgkin's lymphoma (1999) (0)
A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study (2022) (0)
Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E (2020) (0)
The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma (2020) (0)
Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma (2015) (0)
Abstract 5303: Correlative results from PRELUDE, a phase III study of enzastaurin (ENZA) vs placebo (PBO) in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) following a response to R-CHOP therapy (2015) (0)
Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia (2018) (0)
Faculty of 1000 evaluation for The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011) (0)
Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study (2016) (0)
A follow-up of the Mayo Clinic experience in the management of mediastinal masses in Hodgkin's disease and a review of the literature (1992) (0)
Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) (2012) (0)
Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia (2021) (0)
Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity? (2019) (0)
Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments (2021) (0)
Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma. (2016) (0)
Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience (2021) (0)
Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study. (2006) (0)
Long-Term Results of the Treatment of Persons with Hodgkin's Lymphoma in a Resource-Constrained Setting: Real-World Data from a Single Center (2020) (0)
Author reply (2000) (0)
INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E (2021) (0)
An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data. (2014) (0)
Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients (2019) (0)
Beliefs, Attitudes and Utilization of Complementary and Alternative Medicine (CAM) among Long-Term Lymphoma Survivors: A Pilot Study. (2005) (0)
Physical activity and the risk of non‐Hodgkin lymphoma subtypes: A pooled analysis (2022) (0)
CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis. (2012) (0)
Faculty Opinions recommendation of Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. (2010) (0)
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study (2020) (0)
MCL-049: Clinical Characteristics and Outcomes of Primary Versus Secondary Gastrointestinal (GI) Mantle Cell Lymphoma (MCL) (2020) (0)
Central Nervous System Involvement in Peripheral T-Cell Lymphoma (2019) (0)
Hodgkin’s Disease and Non-Hodgkin’s Lymphoma (2001) (0)
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
PF518 SOMATIC COPY NUMBER GAINS IN MYC, BCL2, OR BCL6, IN ADDITION TO TRANSLOCATIONS, IDENTIFIES A SUBSET OF AGGRESSIVE ALTERNATIVE-DH/TH DLBCL PATIENTS (2019) (0)
Epstein Barr Virus–Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease (2021) (0)
Monoclonal antibody therapy for posttransplant lymphoproliferative disorders (2000) (0)
FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma (2022) (0)
Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis. (2021) (0)
Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma. (2018) (0)
Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma (2022) (0)
trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma 1–3 (2013) (0)
The IPI Predicts Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE (2007) (0)
Molecular Landscape of Primary Refractory DLBCL (2022) (0)
Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study (2020) (0)
ASH 2009 meeting report—Top 10 clinically oriented abstracts in lymphoma (2010) (0)
Abstract 1853: Monoclonal B-cell Lymphocytosis (MBL) has increased incidence in non-Hodgkin lymphoma (NHL) Families (2010) (0)
Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data (2015) (0)
Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better? (2021) (0)
Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes (2019) (0)
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder (2018) (0)
Commentary on “CHOP Chemotherapy with Preemptive Granulocyte Colony-Stimulating Factor in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma: A Dose-Intensity Analysis” (2000) (0)
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma (2022) (0)
Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study. (2007) (0)
CD4 1 T-Cell I mmune R esponse t o L arge B -Cell N on- Hodgkin's L ymphoma P redicts P atient O utcome (2001) (0)
Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma (2021) (0)
Absolute lymphocyte count prior to rituximab therapy predicts time to progression in patients with follicular grade 1 lymphoma. (2006) (0)
Abstract 1054: Vaccination history and risk of lymphoma and its major subtypes (2020) (0)
Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma. (2006) (0)
IBCL-333 Follicular Lymphoma (FL) 3B Patients Have a Superior Risk of an Aggressive Disease at First Event Compared to Those With FL1-3A Treated With Front-Line R-CHOP. (2022) (0)
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
Lymphoma occurring during pregnancy (2013) (0)
High-grade B-cell Lymphoma Mimicking an Unresectable Pancreatic Carcinoma: 1187 (2016) (0)
Comprar Mayo Clinic Medical Manual and Mayo Clinic nternal Medicine Review (Two-Volume Set) | Guilherme H.M. Oliveira | 9781420063431 | Informa Healthcare (2007) (0)
Severe Adrenergic Vasomotor Failure Secondary to Cisplatin Chemotherapy (P07.054) (2013) (0)
Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC) (2022) (0)
Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy (2021) (0)
Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways (2019) (0)
Poster: MCL-027 Prognostic Role of Event-Free Survival at 24 Months (EFS24) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (2022) (0)
mantle cell lymphoma 296 DEVELOPMENT OF A SIMPLE DISCRIMINANT FUNCTION SCORE (DF) DIFFERENTIATING ATYPICAL B-CELL CHRONIC LEUKEMIA (ABCLL) FROM MANTLE CELL LYMPHOMA (MCL) (2008) (0)
Acquired Hemophilia A and Hashimoto’s Thyroiditis in a patient with Idiopathic Multicentric Castleman’s Disease: A Case report (2020) (0)
Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era (2019) (0)
Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors (2012) (0)
Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology (2016) (0)
Images and reflections from Mayo Clinic heritage. (2003) (0)
IPI24 supplemental material submitted (2015) (0)
Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma (2022) (0)
Incidence of Leukemia in Olmsted County, Minnesota, 1975 Through 1989 (1995) (0)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) AMIEE.JACKSON, a MICHAELMIAN, c,d CHRISTINAKALPADAKIS, e GERASSIMOSA.PANGALIS, f ANASTASIOSSTATHIS, g ELENAPORRO, g ANNARITACONCONI, h (2015) (0)
Images and reflections from Mayo Clinic heritage. (2002) (0)
Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival (2010) (0)
Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma (2018) (0)
Molecular profiling of diffuse large B-cell lymphoma reveals discrete clusters including one characterized by host inflammatory response (2004) (0)
Advances in the treatment of aggessive lymphomas. Part 3 of a 3-part series: Advances in the treatment of hematologic maliganancies (2005) (0)
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim-PET. (2022) (0)
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra (2015) (0)
DIASTOLIC FUNCTION ASSESSMENT IN NON-HODGKIN LYMPHOMA PATIENTS BY DIFFERENT CUMULATIVE DOSES OF ANTHRACYCLINES (2023) (0)
Recent advances in the treatment of B-cell lymphoma (2009) (0)
Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL). (2021) (0)
Extranodal (EN) and spleen disease by FDG-PET/CT is associated with early clinical failure in untreated follicular lymphoma (FL). (2019) (0)
High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles (2020) (0)
The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance) (2016) (0)
Diffuse large B-cell lymphoma with leukemic involvement. (2021) (0)
Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study (2016) (0)
The synchronous presentation of non-hodgkin's lymphoma and pregnancy: A greater than ten-year follow-up (2000) (0)
No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era (2016) (0)
Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). (2010) (0)
ASH 2010 meeting report‐top 10 clinically oriented abstracts in lymphoma (2011) (0)
Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era (2020) (0)
Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer (2015) (0)
A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408 (2018) (0)
Mayo Internal Medicine Board Review, 2000-2001 (2000) (0)
Reply to ‘Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set’ by Mark J Bishton et al (2008) (0)
Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group (2022) (0)
Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma (2015) (0)
Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis (2021) (0)
A Prognostic Model of 114 Patients with Castleman’s Disease. (2006) (0)
Images and reflections from Mayo Clinic heritage. (2001) (0)
Predictors of disease progression in smoldering Waldenström macroglobulinemia. (2018) (0)
Safety of lenalidomide monotherapy in patients with relapsed or refractory aggressive non-Hodgkin’s lymphom (2008) (0)
Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018 (2018) (0)
62-year-old woman with rapidly evolving dementia. (2000) (0)
Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma. (2016) (0)
MCL-027 Prognostic Role of Event-free Survival at 24 Months (EFS24) in Newly Diagnosed Mantle Cell Lymphoma (MCL). (2022) (0)
Genomic Diversity of Newly Diagnosed Follicular Lymphoma: a Pilot Investigation (2014) (0)
Absolute lymphocyte count predicts overall survival in follicular (2006) (0)
Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease (2013) (0)
Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma. (2009) (0)
Exercise patterns and quality of life among survivors of aggressive lymphoma. (2015) (0)
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials (2022) (0)
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (2022) (0)
Images and reflections from Mayo Clinic heritage. (2002) (0)
with classical Hodgkin lymphoma from that of other diffuse large B-cell lymphomas and shares features The molecular signature of mediastinal large B-cell lymphoma differs (2013) (0)
Clinical trials in lymphoma (2007) (0)
F1000Prime recommendation of Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. (2007) (0)
Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era (2015) (0)
Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. (2019) (0)
Non-Hodgkin’s Lymphoma in the Context of Antecedent Rheumatoid Arthritis: A Case Series from the Mayo Clinic and the Nebraska Lymphoma Study Group. (2004) (0)
Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma (2018) (0)
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course (2022) (0)
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. (2023) (0)
Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma. (2021) (0)
History of autoimmune conditions and lymphoma prognosis (2018) (0)
Adverse Events and Patient Reported Outcomes from Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma in the Involved Site Era (2018) (0)
Abstract 1894: Early adulthood sun exposure, vitamin D related gene variants, and risk of non-Hodgkin lymphoma (2011) (0)
Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma (2010) (0)
Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma, (2011) (0)
Images and reflections from Mayo Clinic heritage. (2001) (0)
Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas (2020) (0)
Outcomes of Adult Burkitt Lymphoma Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) in CR1 Versus ≥ CR2 - a Single Institution Retrospective Analysis (2020) (0)
Psychosocial distress in lymphoma survivors at 3 years’ follow-up. (2017) (0)
Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes (2020) (0)
A Two-Stage Evaluation of Genetic Variation in Immune and In ﬂ ammation Genes with Risk of Non-Hodgkin Lymphoma Identi ﬁ es New Susceptibility Locus in 6p21.3 Region Epidemiology,Biomarkers&Prevention (2012) (0)
NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes. (2004) (0)
Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study. (2022) (0)
126 Risk factors for febrile neutropemia among older patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) treated with anthracycline-based chemotherapy (2006) (0)
THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS (2019) (0)
Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2018) (0)
Exploring Host Germline Genetics to Help Identify Patients with Early Stage Lymphoma Who Might Benefit From the Addition of Radiation Therapy (2018) (0)
Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL) (2014) (0)
Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience. (2007) (0)
Hormone Replacement Therapy and Risk of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia 1 (2002) (0)
IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (2021) (0)
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials. (2019) (0)
Germline Single Nucleotide Polymorphisms (SNPs) in IL1A , IL6 , IL10 , and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). (2006) (0)
Cardiovascular screening in long-term Hodgkin lymphoma survivors. (2014) (0)
Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment (2020) (0)
A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma. (2006) (0)
Abstract 2761: A two-stage evaluation of genetic variation in immune and inflammation genes and risk of non-Hodgkin lymphoma (NHL) (2011) (0)
Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085 [Alliance]). (2015) (0)
Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis (2022) (0)
Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience (2020) (0)
Comprar Mayo Clinic Internal Medicine Concise Textbook | Amit K. Ghosh | 9781420067514 | Informa Healthcare (2007) (0)
LYMPHOID NEOPLASIA GATA-3 expression identi ﬁ es a high-risk subset of PTCL, NOS with distinct molecular and clinical features (2014) (0)
Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: a Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481) (2001) (0)
Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study (2008) (0)
Lymphomas (0)
Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma (2015) (0)
Abstract 877: Aspirin and other nonsteroidal anti-inflammatory drugs, statins, and risk of non-Hodgkin lymphoma (2015) (0)
Outcomes in Primary CNS Lymphoma Post BEAM Autologous Stem Cell Transplantation: A Single-Center Analysis. (2020) (0)
Impact of Metformin Use on the Outcome of Diffuse Large B‐Cell Lymphoma: NHL‐029 (2018) (0)
Management of primary lymphoma of bone (1992) (0)
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy (2022) (0)
Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2 *-Deoxycoformycin and Prediction of Early Relapse 1 (1999) (0)
Improving attendance at medical grand rounds. Authors' reply (2003) (0)
Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium. (2022) (0)
Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma (2013) (0)
Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). (2011) (0)
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma (2012) (0)
Body mass index (BMI) and physical activity in long-term lymphoma survivors: A pilot study. (2006) (0)
GLANZMANN'S THROMBASTHENIA: HEMOSTATIC EFFECTIVENESS OF PLASMA CRYOPRECIPITATE TRANSFUSION (1987) (0)
Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy (2019) (0)
Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma (2015) (0)
Association between bone involvement on PET/CT and event free survival (EFS) in follicular lymphoma (FL) grade 3b. (2020) (0)
Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era (2018) (0)
Genetic variation in the BCL2 pathway and risk of non-hodgkin lymphoma (2007) (0)
Book ReviewsThe LymphomasThe Lymphomas, George P. Canellos, T. Andrew Lister, Jeffrey L. Sklar (Eds.), W. B. Saunders Company, Philadelphia (1998), p. 581, $175, (telephone: 800-545-2522), ISBN: 0-7216-5030-9 (1998) (0)
Images and reflections from Mayo Clinic heritage. (2001) (0)
Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium (2022) (0)
Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women. (2006) (0)
Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies (2012) (0)
Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma (2019) (0)
IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia (2021) (0)
Abstract 1762: Body mass index shows etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin (2016) (0)
Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al. (2019) (0)
Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation. (2007) (0)
Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant (2023) (0)
Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting (2022) (0)
Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis. (2023) (0)
GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells (2010) (0)
Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma (2021) (0)
T-Cell Subsets and Macrophages in the Tumor Microenvironment Are Associated with Early Outcome in Follicular Lymphoma (2017) (0)
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials (2022) (0)
lymphoma survival Prognostic significance of host immune gene polymorphisms in follicular (2013) (0)
Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis (2021) (0)
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis (2022) (0)
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE. (2015) (0)
Preface: why this special series on marginal zone lymphomas? (2021) (0)
A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma (2012) (0)
Images and reflections from Mayo Clinic heritage. (2001) (0)
Bleomycin Pulmonary Toxicity Does Impact on Hodgkin’s Disease Outcome. (2004) (0)
Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes (2021) (0)
Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era (2022) (0)
Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study (2022) (0)
Synchronous presentation of hodgkin's disease and pregnancy: A greater than ten-year follow-up (2000) (0)
Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma (2022) (0)
Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind? (2020) (0)
Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant (2021) (0)
Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma (2013) (0)
Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study. (2006) (0)
Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse (2019) (0)
Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy. (2021) (0)
Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunchemotherapy era. (2013) (0)
NCCTG phase H trial of 2-chlorodeoxyadenosbse (2-CDA) as therapy for previously treated mantle cell lymphoma: Promising single agent activity limited by brief response duration (2000) (0)
Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL (2022) (0)
Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab (2013) (0)
Abstract 741: Evaluation of etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin (2022) (0)
Onset, duration, and clinical impact of immune-related adverse events in Hodgkin lymphoma. (2020) (0)
Mediastinal Large B-Cell Lymphoma : A unique subset of diffuse large B-cell lymphoma with an expression signature resembling that of Hodgkin ’ s Reed-Sternberg Cells (2004) (0)
Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin’s Disease. (2005) (0)
Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia. (1989) (0)
Health behaviors in survivors of aggressive NHL. (2016) (0)
Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes (2021) (0)
The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma (2010) (0)
Sa1334 Celiac Disease is Rare Among Patients With Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, and Hodgkin Lymphoma: A Preliminary Report From the Lymphoma SPORE Molecular Epidemiology Resource (2012) (0)
Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution’s Experience. (2006) (0)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
Randomized, C ontrolled T rial o f a n E asy-to-Read I nformed Consent S tatement f or C linical T rial P articipation: A S tudy o f the E astern C ooperative O ncology G roup (2003) (0)
The significance of gradient expression of chromosome region maintenance protein 1 in large cell lymphoma (2021) (0)
Indolent Lymphomas (2018) (0)
Abstract 1833: Body mass index and physical activity in relation to risk of non-Hodgkin lymphoma (NHL) (2010) (0)
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma (2021) (0)
Utility of restaging bone marrow biopsy (BMB) in PET-negative patients with diffuse large B-cell lymphoma (DLBCL) with bone marrow involvement. (2014) (0)
Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients (2010) (0)
Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI (2012) (0)
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States (2022) (0)
Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL) (2012) (0)
Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome (2022) (0)
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? (2022) (0)
Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL) (2021) (0)
Clinical Characteristics and Outcome of Transformed Diffuse Large B-Cell Lymphoma in the Rituximab Era: A SEER Database Analysis (2017) (0)
Rituximab administration as part of initial therapy may be associated with a poorer outcome in young patients subsequently treated with stem cell transplantation for relapsed chemosensitive large B-cell lymphoma (2005) (0)
Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma. (2005) (0)
Salvage Autologous Stem Cell Transplantation for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Single Institution Experience (2013) (0)
PS1249 EXTRANODAL AND SPLEEN DISEASE DETECTED BY FDG-PET/CT IS ASSOCIATED WITH EARLY CLINICAL FAILURE IN UNTREATED FOLLICULAR LYMPHOMA (2019) (0)
Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (2021) (0)
Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma (2021) (0)
Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome (2021) (0)
Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas. (2006) (0)
Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era (2012) (0)
Abstract B143: Pharmacogenomic of refractory response to R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL) patients (2015) (0)
Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration (2018) (0)
Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy (2022) (0)
SOMATIC COPY NUMBER GAINS IN MYC, BCL2, OR BCL6, IN ADDITION TO TRANSLOCATIONS, IDENTIFIES A SUBSET OF AGGRESSIVE ALTERNATIVE-DH/TH DLBCL PATIENTS (2019) (0)
Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients (2019) (0)
Lymphoma: Clinical trials in lymphoma (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas Matthew Habermann?

Thomas Matthew Habermann is affiliated with the following schools:

New York Medical College
University of California, Los Angeles
University of Wisconsin–Madison
Stanford University
University of Iowa
University of Rochester
University of Nebraska Medical Center